503 related articles for article (PubMed ID: 29268619)
41. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Spencer A; Harrison S; Zonder J; Badros A; Laubach J; Bergin K; Khot A; Zimmerman T; Chauhan D; Levin N; MacLaren A; Reich SD; Trikha M; Richardson P
Br J Haematol; 2018 Jan; 180(1):41-51. PubMed ID: 29076150
[TBL] [Abstract][Full Text] [Related]
42. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Moreau P; Weisel KC; Song KW; Gibson CJ; Saunders O; Sternas LA; Hong K; Zaki MH; Dimopoulos MA
Leuk Lymphoma; 2016 Dec; 57(12):2839-2847. PubMed ID: 27173785
[TBL] [Abstract][Full Text] [Related]
43. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Li Y; Kassir N; Wang X; Palmisano M; Zhou S
J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381
[TBL] [Abstract][Full Text] [Related]
44. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Lacy MQ; Hayman SR; Gertz MA; Dispenzieri A; Buadi F; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Kyle RA; Fonseca R; Bergsagel PL; Roy V; Mikhael JR; Stewart AK; Laumann K; Allred JB; Mandrekar SJ; Rajkumar SV
J Clin Oncol; 2009 Oct; 27(30):5008-14. PubMed ID: 19720894
[TBL] [Abstract][Full Text] [Related]
45. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.
Zhou H; Wang Y; Chen J; He A; Jin J; Lu Q; Zhao Y; Li J; Hou M; Su L; Lai X; Wang W; Liu L; Ma Y; Gao D; Lai W; Zhou X; Jing H; Zhang J; Yang W; Ran X; Lin C; Hao J; Xiao T; Huang Z; Zhu Z; Wang Q; Fang B; Wang B; Song Y; Cai Z; Liu B; Zhu Y; Yang X; Kang X; Li J; Chen W
Ann Hematol; 2024 Mar; 103(3):855-868. PubMed ID: 38112795
[TBL] [Abstract][Full Text] [Related]
47. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Schjesvold FH; Richardson PG; Facon T; Alegre A; Spencer A; Jurczyszyn A; Sunami K; Frenzel L; Min CK; Guillonneau S; Lin PL; Le-Guennec S; Campana F; van de Velde H; Bensfia S; Bringhen S
Haematologica; 2021 Apr; 106(4):1182-1187. PubMed ID: 32586908
[No Abstract] [Full Text] [Related]
48. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
49. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T
Am J Hematol; 2021 Nov; 96(11):E423-E427. PubMed ID: 34383345
[No Abstract] [Full Text] [Related]
50. Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.
Conticello C; Parisi M; Romano A; Calafiore V; Ancora F; La Fauci A; Consoli ML; Di Raimondo F
Future Oncol; 2017 Feb; 13(5s):3-6. PubMed ID: 28116941
[TBL] [Abstract][Full Text] [Related]
51. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Dimopoulos M; Bringhen S; Anttila P; Capra M; Cavo M; Cole C; Gasparetto C; Hungria V; Jenner M; Vorobyev V; Ruiz EY; Yin JY; Saleem R; Hellet M; Macé S; Paiva B; Vij R
Blood; 2021 Mar; 137(9):1154-1165. PubMed ID: 33080623
[TBL] [Abstract][Full Text] [Related]
52. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
53. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.
Song KW; Dimopoulos MA; Weisel KC; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Monzini MS; Zaki M; Jacques C; San Miguel J
Haematologica; 2015 Feb; 100(2):e63-7. PubMed ID: 25425684
[No Abstract] [Full Text] [Related]
54. [Daratumumab for multiple myeloma].
Croizier C; Bailly S
Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
[TBL] [Abstract][Full Text] [Related]
55. Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.
Han X; Jiang X; He J; Zheng G; Xiong Y; Wen Y; Yang Y; He D; Chen Q; Zhao Y; Li Y; Wu W; Cai Z
Cancer Med; 2024 May; 13(9):e7232. PubMed ID: 38698679
[TBL] [Abstract][Full Text] [Related]
56. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.
Dimopoulos M; Weisel K; van de Donk NWCJ; Ramasamy K; Gamberi B; Streetly M; Offidani M; Bridoux F; de la Rubia J; Mateos MV; Ardizzoia A; Kueenburg E; Collins S; Di Micco A; Rosettani B; Li Y; Bacon P; Sonneveld P
J Clin Oncol; 2018 Jul; 36(20):2035-2043. PubMed ID: 29394124
[TBL] [Abstract][Full Text] [Related]
57. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
[TBL] [Abstract][Full Text] [Related]
58. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
Moreau P; Dimopoulos MA; Richardson PG; Siegel DS; Cavo M; Corradini P; Weisel K; Delforge M; O'Gorman P; Song K; Chen C; Bahlis N; Oriol A; Hansson M; Kaiser M; Anttila P; Raymakers R; Joao C; Cook G; Sternas L; Biyukov T; Slaughter A; Hong K; Herring J; Yu X; Zaki M; San-Miguel J
Eur J Haematol; 2017 Sep; 99(3):199-206. PubMed ID: 28504846
[TBL] [Abstract][Full Text] [Related]
59. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
Richardson PG; Beksaç M; Špička I; Mikhael J
Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
[TBL] [Abstract][Full Text] [Related]
60. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
Martin TG; Capra M; Mohty M; Suzuki K; Quach H; Cavo M; Moreau P; Dimopoulos M; Yong K; Tekle C; Foster MC; Barnes Y; Risse ML; Mikhael J
Transplant Cell Ther; 2023 Feb; 29(2):134.e1-134.e7. PubMed ID: 36372355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
